Welcome to CKB CORE's new home! Please be sure to update any bookmarks you may have.
×

Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05185739
Title Perioperative Pembrolizumab and Lenvatinib in Resectable Hepatocellular Carcinoma (HCC) (PRIMER-1)
Acronym PRIMER-1
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors University College, London
Indications
Therapies
Age Groups: adult | senior
Covered Countries GBR


No variant requirements are available.